Jason Grant Kettle

USPTO Granted Patents = 31 (Patent Applications = 8)

CIPO Patents = 1 (Patent Applications = 9)

EPO Patents = 7 (Patent Applications = 14)

Average Co-Inventor Count = 3.7

ph-index = 7

Forward Citations = 184(Granted Patents)

Location History:

Macklesfield, GB (2006)
Cheshire, GB (2013)
Macclesfield, GB (2001 - 2022)
Cambridge, GB (2019 - 2024)

Company Filing History:

Dizal (jiangsu) Pharmaceutical Co., Ltd.

Astra Zeneca U.k. Limited

Years Active: 2001-2025

Loading Chart...

31 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12410187 - Fused tricyclic compounds useful as anticancer agents (2025-09-09),

2. 11897869 - JAK1 selective inhibitors (2024-02-13),

3. 11851432 - Triazolopyrimidine compounds and their use in treating cancer (2023-12-26),

4. 11407765 - Tetracyclic heteroaryl compounds (2022-08-09),

5. 11247983 - Compounds and methods for inhibiting JAK (2022-02-15),

6. 11084827 - Triazolopyrimidine compounds and their use in treating cancer (2021-08-10),

7. 11053223 - Phenoxyquinazoline compounds and their use in treating cancer (2021-07-06),

8. 10961228 - JAK1 selective inhibitors (2021-03-30),

9. 10829479 - C-anilinoquinazoline compounds and their use in treating cancer (2020-11-10),

10. 10654835 - Compounds and methods for inhibiting JAK (2020-05-19),

11. 10597405 - Chemical compounds (2020-03-24),

12. 10519152 - Compounds and their use in treating cancer (2019-12-31),

13. 10273227 - C5-anilinoquinazoline compounds and their use in treating cancer (2019-04-30),

14. 10167276 - Compounds and methods for inhibiting JAK (2019-01-01),

15. 9714236 - Compounds and methods for inhibiting JAK (2017-07-25),

Title: Jason Grant Kettle: Innovator in Cancer Treatment

Introduction

Jason Grant Kettle is a prolific inventor based in Macclesfield, GB, known for his significant contributions to the field of pharmaceutical sciences. With an impressive portfolio of 29 patents, Kettle has played a pivotal role in advancing cancer treatment methodologies. His work focuses primarily on novel compounds that have the potential to combat cell proliferative disorders effectively.

Latest Patents

Among his latest patents are innovations related to triazolopyrimidine compounds, specifically their applications in treating cancer. Kettle's inventive process encompasses compounds of Formula (I) and further includes tetracyclic heteroaryl compounds and their pharmaceutically acceptable salts. The specifications extend to various processes and intermediates required for their preparation, as well as the pharmaceutical compositions developed from these compounds, aiming to enhance treatment options for patients suffering from similar ailments.

Career Highlights

Throughout his career, Jason Grant Kettle has been associated with leading pharmaceutical companies, including AstraZeneca AB and Dizal (Jiangsu) Pharmaceutical Co., Ltd. His tenure in these organizations has allowed him to further his research and development efforts in pharmaceutical innovation, particularly in the area of oncology.

Collaborations

Kettle has collaborated with notable colleagues such as Alan Wellington Faull and Andrew John Barker. These partnerships are testament to the intricate work involved in developing new therapeutic solutions and highlight the importance of teamwork in scientific advancement.

Conclusion

Jason Grant Kettle's extensive patent portfolio and his ongoing contributions to pharmaceutical research underline his status as a key innovator in the fight against cancer. His commitment to discovering novel therapeutic compounds not only showcases his ingenuity but also represents a significant impact on the medical community, offering hope to countless patients worldwide.

This text is generated by artificial intelligence and may not be accurate.